ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financi...(ase3 program as we head toward the antic...),Health

Date:2/27/2008

ase 3 program as we head toward the anticipated filing of our initial NDA and MAA filings next year. As we enter 2008, we also have stronger teams in place to reach our development goals and generate future growth, both here in the U.S. and in the E.U. We will appropriately spend more in 2008 compared to 2007, which is, reflected in our expense guidance for 2008. This is consistent with our expectations and goal to ultimately deliver important, novel therapeutics to patients and physicians."

de Rosen continued, "Also, 2007 was another year of strong Vancocin performance; we achieved net product sales of $204 million, representing growth of 22 percent over that of 2006. We anticipate that our new marketing initiatives will help us garner additional growth in 2008 and beyond, potentially offsetting a slow down in the incidence rate of C. difficile infection (CDI). At ViroPharma, we take our commitment to the safety of patients with CDI very seriously. Through our efforts during the year, physicians were better educated to identify patients at high risk of disease, hospitals are better equipped to control CDI, and patients at risk of severe and complicated disease were assured of a proven safe and effective treatment. Importantly, though, our efforts in CDI are also focused on future treatment alternatives: we made progress toward a potential future treatment for disease recurrence, called NTCD, which we expect to enter the clinic this year."

Net income in the fourth quarter and twelve months ended December 31, 2007 was $20.4 million and $95.4 million, respectively, compared to net income of $18.0 million and $66.7 million for the same periods in 2006. Net income per share for the quarter ended December 31, 2007 was $0.29 per share, basic and $0.25 per share, diluted, compared to a net income of $0.26 per share, basic, and $0.25 per share, diluted, for the same period in 2006. Net income per share for the twelve months ended December 31, 2007 was $1.37 pe
'/>"/>

SOURCE ViroPharma Incorporated Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related medicine news :

1. ViroPharma to Present at the Maxim Group First Annual Growth Conference
2. ViroPharma to Present at the UBS Global Life Sciences Conference
3. ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results
4. ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM)
5. ViroPharma to Present at the 26th Annual JP Morgan Healthcare Conference
6. ViroPharma Augments Senior Management
7. ViroPharma Provides Update on Vancocin(R)
8. Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma
9. Accuray Incorporateds CEO to Speak at UBS Global Life Sciences Conference
10. Accuray Incorporated to Report First Quarter Fiscal Year 2008 Financial Results
11. Aflac Incorporated to Release Third Quarter Results On October 23, 2007